Protara Therapeutics (TARA) Retained Earnings (2013 - 2026)
Protara Therapeutics (TARA) recorded quarterly Retained Earnings of -$320.2 million in Q1 2026, down 5.88% quarter-over-quarter from -$302.4 million in Q4 2025, and down 359876.4% on a YoY basis from N/an in Q1 2025.
Protara Therapeutics (TARA) Retained Earnings (2013 - 2026) Analysis & Trends
Protara Therapeutics' Retained Earnings history runs 14 years deep, the most recent figure standing at -$320.2 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 359876.4% year-over-year to -$320.2 million; the TTM figure through Mar 2026 stood at -$320.2 million (down 359876.4% YoY), while the FY2025 annual figure was -$302.4 million, down 15121050.0% from the prior year.
- Retained Earnings was -$320.2 million for Q1 2026 at Protara Therapeutics, down from -$302.4 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $89000.0 in Q1 2025 to a low of -$320.2 million in Q1 2026.
- Historically, Retained Earnings has averaged -$130.5 million across 5 years, with a median of -$121.0 million in 2022.
- The sharpest annual moves came in 2024 and 2025: Retained Earnings surged 117.58% in 2024, then plunged 15121050.0% in 2025.
- A 5-year view of Retained Earnings shows it stood at -$688000.0 in 2022, then slumped by 29025.58% to -$200.4 million in 2023, then soared by 100.0% to $2000.0 in 2024, then slumped by 15121050.0% to -$302.4 million in 2025, then dropped by 5.88% to -$320.2 million in 2026.
- The last three Retained Earnings figures came in at -$320.2 million (Q1 2026), -$302.4 million (Q4 2025), and -$285.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -279.00 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | 130.89 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -838.07 Mn |
| 10 | Protara Therapeutics | 216.35 Mn | 216.35 Mn | - | -320.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -320.20 Mn |
| Dec 31, 2025 | -302.42 Mn |
| Sep 30, 2025 | -285.11 Mn |
| Jun 30, 2025 | -271.85 Mn |
| Mar 31, 2025 | 89,000.00 |
| Dec 31, 2024 | 2,000.00 |
| Sep 30, 2024 | 29,000.00 |
| Jun 30, 2024 | -220.99 Mn |
| Mar 31, 2024 | -211.48 Mn |
| Dec 31, 2023 | -200.38 Mn |
| Sep 30, 2023 | -165,000.00 |
| Jun 30, 2023 | -336,000.00 |
| Mar 31, 2023 | -169.01 Mn |
| Dec 31, 2022 | -688,000.00 |
| Sep 30, 2022 | -121.00 Mn |
| Jun 30, 2022 | -113.31 Mn |
| Mar 31, 2022 | -942,000.00 |
| Dec 31, 2021 | -211,000.00 |
| Sep 30, 2021 | -83.78 Mn |
| Jun 30, 2021 | -101,000.00 |